Peak Bronchoprotection Conferred by Levosalbutamol and Racemic Salbutamol
Status:
Withdrawn
Trial end date:
2010-01-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to compare the peak dose relative bronchoprotection offered by
levosalbutamol and racemic salbutamol in mild to moderate asthmatics preselected into two
groups on the basis of their beta-2 adrenoreceptor polymorphisms.